The Cash Cow Is Out of Milk

ViroPharma (Nasdaq: VPHM  ) has milked Vancocin pretty well, but it looks like the cash cow is finally running dry.

The company bought the rights to the antibiotic from Eli Lilly (NYSE: LLY  ) for $120 million in 2004. Not a bad pickup, considering that the drug brought in revenue of $110 million in just the first half of this year.

Vancocin hasn't been under patent for many years now, but generic-drug makers like Teva Pharmaceutical (Nasdaq: TEVA  ) and Novartis (NYSE: NVS  ) haven't tried to make knockoffs of the drug because the Food and Drug Administration required generics to undergo clinical trials before approval. The increased cost acted as a barrier to entry and helped ViroPharma develop its cash cow.

More than three years ago, the FDA said it was considering letting generics onto the market with less-expensive laboratory tests. As the agency twiddled its thumbs, ViroPharma kept on milking.

Unfortunately, the FDA finally got around to convening a panel of experts Tuesday, and they unanimously agreed that the agency should approve generic versions of Vancocin without requiring them to be tested in clinical trials.

Both Mylan (Nasdaq: MYL  ) and Akorn have gotten in line for an approval. The Office of Generic Drugs works differently than the branded side of the agency. There are no PDUFA dates for generic drugs, so there's no telling how quickly it might approve the first generic competition.

So where does that leave ViroPharma once it loses its cash cow? It still has an up-and-coming drug, Cinryze, which treats hereditary angioedema, a rare swelling disease. With $267 million in cash and equivalents, the company is in OK shape to start rebuilding its pipeline. ViroPharma may also become a takeover target for a larger orphan-drug maker like Genzyme (Nasdaq: GENZ  ) or BioMarin Pharmaceutical (Nasdaq: BMRN  ) .

Cash in with more Foolishness:

Start investing today – just $7 per trade with Scottrade. Or find the broker that's right for you.

BioMarin Pharmaceutical is a Motley Fool Rule Breakers pick and Novartis is a Global Gains selection. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 11, 2009, at 3:23 AM, DannyHaszard wrote:

    Eli Lilly has received the largest criminal fine ever against a drug company over their Zyprexa cash cow,add it all up comes to $4.6 billion, in Zyprexa settlements,fines,litigation.

    We put Lilly products in our babies they really need to clean up their act and quit with the white wash.

    Daniel Haszard http://www.zyprexa-victims.com

    WARNING-

    If a drug (Zyprexa) lists anything about the pancreas among the side effects, it probably means it can cause diabetes.

    Unlike your liver, the pancreas does not regenerate itself. If it gets damaged, diabetes is very likely.

    Zyprexa is glorified Thorazine at ten times the price

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 958251, ~/Articles/ArticleHandler.aspx, 11/22/2014 5:46:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement